1. Show article details.

    BRIEF-Regulus Says First Patient Dosed In Phase 1B Clinical Trial Of RGLS4326 For The Treatment Of Patients With Autosomal Dominant Polycystic Kidney Disease

    Reuters – 9:20 AM ET 10/15/2020

    Regulus Therapeutics Inc (RGLS): * REGULUS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B CLINICAL TRIAL OF RGLS4326 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Source text for Eikon: Further company coverage:

  2. Show article details.

    Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    PR Newswire – 8:07 AM ET 10/15/2020

    LA JOLLA, Calif.

  3. Show article details.

    BRIEF-Regulus Therapeutics Announces Receipt Of $5 Mln Milestone And Material Payments From Sanofi

    Reuters – 8:13 AM ET 10/13/2020

    Regulus Therapeutics Inc (RGLS): * REGULUS THERAPEUTICS ANNOUNCES RECEIPT OF $5 MILLION MILESTONE AND MATERIAL PAYMENTS FROM SANOFI. * Regulus Therapeutics Inc (RGLS) - PROCEEDS USED TO REPAY DEBT PRINCIPAL WITH OXFORD FINANCE. * Regulus Therapeutics Inc (RGLS) - REDUCED REMAINING PRINCIPAL DUE UNDER TERM LOAN TO ABOUT $9.6 MILLION Source text for Eikon: Further company coverage:

  4. Show article details.

    Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi

    PR Newswire – 8:07 AM ET 10/13/2020

    LA JOLLA, Calif. In August 2020, the Company entered into an amendment with Sanofi concerning the receipt of potential milestones from Sanofi for its development of miR-21 programs.

  5. Show article details.

    Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference

    PR Newswire – 8:07 AM ET 09/11/2020

    LA JOLLA, Calif.

  6. Show article details.

    Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference

    PR Newswire – 8:07 AM ET 09/03/2020

    LA JOLLA, Calif.

  7. Show article details.

    BRIEF-Regulus Therapeutics Announces Restructuring Of Sanofi And Oxford Loan Agreements

    Reuters – 8:18 AM ET 08/31/2020

    Regulus Therapeutics Inc (RGLS): * REGULUS THERAPEUTICS ANNOUNCES RESTRUCTURING OF SANOFI AND OXFORD LOAN AGREEMENTS. * REGULUS THERAPEUTICS ANNOUNCES RESTRUCTURING OF SANOFI AND OXFORD LOAN AGREEMENTS. * REGULUS - ENTERED INTO AMENDMENT WITH SANOFI CONCERNING RECEIPT OF POTENTIAL MILESTONES FROM SANOFI FOR ITS DEVELOPMENT OF MIR-21 PROGRAMS.

  8. Show article details.

    Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements

    PR Newswire – 8:07 AM ET 08/31/2020

    LA JOLLA, Calif. Concurrently with the Oxford amendment described above, the Company also entered into an amendment with Sanofi concerning the receipt of potential milestones from Sanofi for its development of miR-21 programs. "We are pleased to enter into these two amended agreements with our partner, Sanofi, and with our lender, Oxford," stated Jay Hagan, CEO of Regulus.

  9. Show article details.

    Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors

    Business Wire – 7:30 AM ET 08/17/2020

    Dr. Menzel brings significant leadership in the global healthcare sector Stoke Therapeutics, Inc. (STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Garry E. Menzel, Ph.D., to both its Board of Directors and Compensation Committee.

  10. Show article details.

    BRIEF-Regulus Therapeutics Reports QTRLY Loss Per Share Of $0.23

    Reuters – 4:25 PM ET 08/13/2020

    Regulus Therapeutics Inc (RGLS): * REGULUS THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT UPDATES. * Regulus Therapeutics Inc (RGLS) - QTRLY LOSS PER SHARE $0.23 Source text for Eikon: Further company coverage:

  11. Show article details.

    Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates

    PR Newswire – 4:07 PM ET 08/13/2020

    LA JOLLA, Calif. "We are pleased with the progress of our ADPKD program and the completion of dosing of the MAD clinical study for RGLS4326 in healthy volunteers," said Jay Hagan, CEO of Regulus. Second Quarter 2020 Corporate Highlights and Recent Updates Appointment of Chief Scientific Officer: In August, Dr. Denis Drygin joined Regulus as its Chief Scientific Officer.

  12. Show article details.

    Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

    PR Newswire – 8:07 AM ET 08/06/2020

    LA JOLLA, Calif.

  13. Show article details.

    Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer

    PR Newswire – 8:07 AM ET 08/03/2020

    LA JOLLA, Calif. "We are excited to announce the addition of Denis to the Regulus leadership team," said Jay Hagan, CEO of Regulus. Dr. Drygin joins Regulus from Pimera, where he was founder and Vice President of Research and Development since 2013.

Page:

Today's and Upcoming Events

  • Nov
    10

    RGLS to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    13

    RGLS announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.